The feasibility , accuracy, and impact of xpert MTB/RIF testing in a remote aboriginal community in Canada

Chest

Volumn 148, Issue 3, 2015, Pages 767-773

  Alvarez, Gonzalo G ^a   Van Dyk, Deborah D ^a   Desjardins, Marc ^b   Yasseen, Abdool S ^a   Aaron, Shawn D ^a   Cameron, D William ^a   Obed, Natan ^c   Baikie, Maureen ^d   Pakhale, Smita ^a   Denkinger, Claudia M ^e   Sohn, Hojoon ^e   Pai, Madhukar ^e  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CCW 4240B The Ottawa Hospital General Campus   (Canada)

^c Nunavut Tunngavik Inc   (Canada)

^d Government of Nunavut   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; CANADA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; FEMALE; GOLD STANDARD; HUMAN; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TIME TO TREATMENT; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; TURNAROUND TIME; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; INCIDENCE; INUIT; ISOLATION AND PURIFICATION; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUBERCULOSIS, PULMONARY;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, BACTERIAL; FEASIBILITY STUDIES; FEMALE; HUMANS; INCIDENCE; INUITS; MALE; MYCOBACTERIUM TUBERCULOSIS; NUNAVUT; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84941639953     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2948     Document Type: Article

References (15)

1. Alvarez GG, Orr P, Wobeser WL, Cook V, Long R. Tuberculosis prevention and care in First Nations, Inuit, and Metis people. Canadian tuberculosis standards, 7th edition. Can Respir J. 2013; 20( suppl A): 44A-53A.
2. Public Health Agency of Canada. Tuberculosis in Canada 2010-Pre-Release. Gatineau, QC, Canada: Minister of Public Works and Government Services Canada; 2012.
3. Tait H. A boriginal Peoples Survey, 2006: Inuit Health and Social Conditions. Ottawa, ON, Canada: Statistics Canada; 2008.
4. Halverso J, Ellis E, Gallant V, Archibald C. Epidemiology of tuberculosis in Canada. Canadian tuberculosis standards, 7th edition. Can Respir J. 2013; 20 ( suppl A): 4A-8A.
5. FDA permits marketing of first US test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. US Food and Drug Administration website. http://www. fda. gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm362602. htm. Accessed September 1, 2014.
6. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363 ( 11): 1005-1015.
7. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and eff ectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet. 2011; 377 ( 9776): 1495-1505.
8. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; 1 : CD009593.
9. Deggim V, Somoskovi A, Voit A, Böttger EC, Bloemberg GV. Integrating the Xpert MTB/RIF assay into a diagnostic workfl ow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area. J Clin Microbiol. 2013; 51 ( 7): 2396-2399.
10. Sohn H, Aero AD, Menzies D, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis. 2014; 58 ( 7): 970-976.
11. NHS aboriginal population profi le, 2011. Statistics Canada website. http://www12. statcan. gc. ca/nhs-enm/2011/dp-pd/aprof/ index. cfm?Lang=E. Accessed September 1, 2014.
12. Bossuyt PM, Reitsma JB, Bruns DE, et al; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003; 138 ( 1): 40-44.
13. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986; 104 ( 1): 66-73.
14. Drain PK, Hyle EP, Noubary F, et al. Diagnostic point-of-care tests in resourcelimited settings. Lancet Infect Dis. 2014; 14 ( 3): 239-249.
15. Lippincott CK, Miller MB, Popowitch EB, Hanrahan CF, Van Rie A. Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clin Infect Dis. 2014; 59 ( 2): 186-192.